NCT05933967RecruitingPhase 2
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
A Phase II, Prospective ,Multicenter Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
Source: ClinicalTrials.gov · Last updated 15 Aug 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- First submitted
- 16 Jun 2023
- Start date
- 1 Jun 2023
- Primary completion date
- 30 Dec 2024
- Lead sponsor
- Shandong Cancer Hospital and Institute
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT05933967
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 31
- From 1 Jun 2023 to the primary completion date, 30 Dec 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- • systemic lymphoma involved CNS.
- Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue diseases.
- uncontrolled infections (including HBV, HCV, HIV/AIDS)
- Subjects who prepared for transplantation
- Pregnancy or active lactation
Who the study is looking for
- Newly diagnosed Double Expression Diffuse Large B-cell Lymphoma
- Age 18-70 years
- ECOG performance status 0-2
- Ann Arbor stage II-IV
- 8.Subjects who in line with the testing standard of the clinical trial laboratory
- Life expectancy ≥ 3months
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Coordinator of this site? Confirm its status | Jinan | China | Recruiting |
| The First Ailliated Hospital of Nanchang University Coordinator of this site? Confirm its status | Nanchang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.